Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
The FDA has approved the supplemental New Drug Application for Imbruvica® (ibrutinib;Janssen) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
A newly developed international prognostic score may be a useful clinical management tool to predict the likelihood of required treatment for patients with early-stage CLL.
Compromised immune status could have effects on disease.
